AI Engines For more Details: Perplexity Kagi Labs You
Antimalarial Activity: Halofantrine is effective against Plasmodium falciparum malaria, including strains that are resistant to other antimalarial drugs like chloroquine and sulfadoxine-pyrimethamine.
Treatment of Malaria: Halofantrine is typically used for the treatment of uncomplicated malaria in areas where the parasite is known or likely to be resistant to other antimalarial drugs. It is not recommended for the prevention of malaria.
Mode of Action: Halofantrine acts by interfering with the function of heme polymerase in the parasite, leading to the accumulation of toxic heme metabolites within the malaria parasite and subsequent death.
Rapid Onset of Action: Halofantrine has a relatively rapid onset of action, with clinical improvement typically seen within 24 to 48 hours after initiation of treatment.
High Cure Rate: When used as directed, halofantrine has been shown to have a high cure rate for uncomplicated falciparum malaria. However, its effectiveness may be limited by the emergence of drug-resistant strains of the malaria parasite.
Adverse Effects: Common adverse effects associated with halofantrine include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain. These symptoms are usually mild to moderate in severity and transient.
Cardiac Effects: Halofantrine has been associated with potentially serious cardiac adverse effects, including prolongation of the QT interval on electrocardiogram (ECG), which can predispose patients to a rare but potentially fatal arrhythmia known as torsades de pointes. Due to this risk, halofantrine is contraindicated in individuals with a history of cardiac arrhythmias or prolonged QT interval, as well as those taking other medications that may prolong the QT interval or inhibit halofantrine metabolism.
Monitoring: Patients receiving halofantrine therapy should undergo regular monitoring of cardiac function, including baseline and periodic ECG assessments. Treatment should be discontinued if significant cardiac abnormalities or arrhythmias develop.
Hepatic Effects: Rare cases of hepatotoxicity, including hepatitis and elevated liver enzymes, have been reported with halofantrine use. Patients should be monitored for signs and symptoms of liver dysfunction during treatment.
Drug Interactions: Halofantrine may interact with other medications, particularly those that prolong the QT interval or inhibit its metabolism. Concomitant use of halofantrine with such medications should be avoided or carefully monitored.
Pregnancy and Lactation: The safety of halofantrine use during pregnancy and lactation has not been established. It should be used with caution in pregnant or breastfeeding women, weighing the potential benefits against the risks to the mother and fetus or infant.
Resistance: As with other antimalarial drugs, the emergence of drug-resistant strains of Plasmodium falciparum may limit the effectiveness of halofantrine over time. Therefore, it is important to monitor for resistance patterns and adjust treatment strategies accordingly.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| ADHD | 1.1 | 0.5 | 1.2 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.1 | 4 |
| Allergic Rhinitis (Hay Fever) | 1.1 | 1.1 | |
| Allergies | 1 | 0.9 | 0.11 |
| Allergy to milk products | 0 | 0.1 | 0 |
| Alopecia (Hair Loss) | 0.5 | 0.5 | |
| Alzheimer's disease | 0.7 | 4.6 | -5.57 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.2 | 1.2 | |
| Ankylosing spondylitis | 1.6 | 1.5 | 0.07 |
| Anorexia Nervosa | 0.1 | 1.8 | -17 |
| Antiphospholipid syndrome (APS) | 1.4 | 0.3 | 3.67 |
| Asthma | 0.8 | 0.5 | 0.6 |
| Atherosclerosis | 1.5 | -1.5 | |
| Atrial fibrillation | 1.7 | 1.4 | 0.21 |
| Autism | 3.9 | 5.2 | -0.33 |
| Barrett esophagus cancer | 0.2 | -0.2 | |
| Bipolar Disorder | 0.4 | 1 | -1.5 |
| Brain Trauma | 0.5 | -0.5 | |
| Carcinoma | 1.4 | 0.4 | 2.5 |
| Celiac Disease | 0.4 | 1.2 | -2 |
| Cerebral Palsy | 0.2 | 0.8 | -3 |
| Chronic Fatigue Syndrome | 2.8 | 1.5 | 0.87 |
| Chronic Kidney Disease | 1.5 | 2.1 | -0.4 |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.2 | 1.1 | 0.09 |
| Chronic Urticaria (Hives) | 0.2 | 1 | -4 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 1 | -2.33 |
| Colorectal Cancer | 1.5 | 0.5 | 2 |
| Constipation | 0.7 | 0.8 | -0.14 |
| Coronary artery disease | 1.5 | 0.4 | 2.75 |
| COVID-19 | 2.5 | 7.7 | -2.08 |
| Crohn's Disease | 2.7 | 3.5 | -0.3 |
| cystic fibrosis | 0.5 | -0.5 | |
| deep vein thrombosis | 0.7 | -0.7 | |
| Depression | 3.8 | 3.2 | 0.19 |
| Dermatomyositis | 0.2 | 0.2 | |
| Eczema | 1 | 1.1 | -0.1 |
| Endometriosis | 0.7 | 0.5 | 0.4 |
| Epilepsy | 0.6 | 0.4 | 0.5 |
| Fibromyalgia | 0.9 | 1.1 | -0.22 |
| Functional constipation / chronic idiopathic constipation | 1.8 | 1.6 | 0.13 |
| gallstone disease (gsd) | 0.4 | 0.5 | -0.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.8 | -3 |
| Generalized anxiety disorder | 1.3 | 0.1 | 12 |
| Glioblastoma | 0.2 | -0.2 | |
| Gout | 0.1 | -0.1 | |
| Graves' disease | 0.1 | 0.8 | -7 |
| Halitosis | 0 | 0.2 | 0 |
| Hashimoto's thyroiditis | 0.8 | 0.4 | 1 |
| Hidradenitis Suppurativa | 0.5 | 0.5 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.6 | 1.3 | 0.23 |
| hyperglycemia | 0.4 | -0.4 | |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 0.4 | 2.5 | -5.25 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 0.1 | 0.1 | |
| IgA nephropathy (IgAN) | 3 | -3 | |
| Inflammatory Bowel Disease | 2.5 | 5 | -1 |
| Insomnia | 0.5 | 1 | -1 |
| Intelligence | 0.1 | 0.9 | -8 |
| Intracranial aneurysms | 0.4 | 0.4 | |
| Irritable Bowel Syndrome | 0.7 | 1.3 | -0.86 |
| Liver Cirrhosis | 1.6 | 1.2 | 0.33 |
| Long COVID | 3.6 | 4 | -0.11 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.3 | -0.3 | |
| ME/CFS with IBS | 0.3 | 0.8 | -1.67 |
| ME/CFS without IBS | 2.5 | 0.3 | 7.33 |
| Metabolic Syndrome | 3 | 2.7 | 0.11 |
| Mood Disorders | 4.2 | 3.6 | 0.17 |
| multiple chemical sensitivity [MCS] | 1.1 | 0.3 | 2.67 |
| Multiple Sclerosis | 3 | 4 | -0.33 |
| Multiple system atrophy (MSA) | 1.1 | 0.3 | 2.67 |
| Neuropathy (all types) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.4 | 2.4 | -0.71 |
| Obesity | 3.6 | 1.7 | 1.12 |
| obsessive-compulsive disorder | 1.6 | 2.8 | -0.75 |
| Osteoarthritis | 1.3 | 1.3 | |
| Osteoporosis | 0.4 | 0.3 | 0.33 |
| pancreatic cancer | 0.2 | 0.2 | |
| Parkinson's Disease | 1.1 | 3.1 | -1.82 |
| Polycystic ovary syndrome | 0.6 | 0.5 | 0.2 |
| Postural orthostatic tachycardia syndrome | 0.1 | -0.1 | |
| Premenstrual dysphoric disorder | 0.3 | 0.1 | 2 |
| primary biliary cholangitis | 0 | 0 | |
| Psoriasis | 0.6 | 1.8 | -2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.3 | 0.7 | 5.14 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 1.4 | 0.8 | 0.75 |
| scoliosis | 0.1 | 1.3 | -12 |
| Sjögren syndrome | 1.5 | 0.9 | 0.67 |
| Sleep Apnea | 0.4 | 1.3 | -2.25 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.2 | |
| Stress / posttraumatic stress disorder | 0.7 | 1.4 | -1 |
| Systemic Lupus Erythematosus | 2.4 | 1.3 | 0.85 |
| Tic Disorder | 0.2 | 0.9 | -3.5 |
| Tourette syndrome | 0 | 0 | |
| Type 1 Diabetes | 0.9 | 1.4 | -0.56 |
| Type 2 Diabetes | 3.1 | 1.6 | 0.94 |
| Ulcerative colitis | 0.7 | 2.1 | -2 |
| Unhealthy Ageing | 2.4 | 1.6 | 0.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.